The role of non-alcoholic fatty liver disease in cardiovascular disease

European Cardiology Review

Volumn 9, Issue 1, 2014, Pages 10-15

  Francque, Sven M ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cardiovascular events; Non alcoholic fatty liver disease; Pathophysiology; Steatosis

Indexed keywords

ALPHA TOCOPHEROL; AUTACOID; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDIATOR RELEASE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; RISK REDUCTION;

EID: 84939513762     PISSN: 17583756     EISSN: 17583764     Source Type: Journal    
DOI: 10.15420/ecr.2014.9.1.10     Document Type: Article

References (113)

1. Francque S, Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohopatitls (NASH), in: van Damme P, van Herck K, Micnielsen P, et al., Chronic hepatitis and liver disease, Oxford Textbook of Public Health, 5th edition, Oxford: Oxford university Press, 2009:1249-63.
2. Vernon G, Baranova A, Younossi ZM, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatltls In adults, Aliment Pharmacol Ther, 2011;34(3):274-85.
3. Verrijken A, Francque S, Van Gaal L, The metabolic syndrome and the liver, Acta Gastroenterol Belg, 2008;71(1):48-59.
4. Brunt EM, Janney CG, Di Bisceglle AM, et al., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 1999;94(9):2467-74.
5. Anstee QM, Targher G, Day CP, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 2013,10(6):330-44.
6. Ballestri S, Lonardo A, Bonapace S, et al., Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease, World J Gastroenterol, 2014;20(7):1724-45.
7. Brunt EM, Histopathology of non-alcoholic fatty liver disease, Clin Liver Dis, 2009;13(4):533-44.
8. Begriche K, Massart J, Robin MA, et al., Drug-Induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver, J Hepatol, 2011;54(4):773-94.
9. Kotronen A, Seppänen-Laakso T, Westerbacka J, et al., Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum, Obesity (Silver Spring), 2010;18(5):937-44.
10. Paradis V, Bedossa P, Definition and natural history of metabolic steatosis: histology and cellular aspects, Diabetes Metab, 2008:34(6 Pt 2):638-42.
11. Ratziu V, Bellentani S, Cortez-Plnto H, et al., A position statement on NAFLD/NASI I based on the EASL 2009 special conference, J Hepatol, 2010;53(2):372-84.
12. Chalasani N, Younossi Z, Lavlne JE, et al., The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Am J Gastroenterol. 2012;107(6):811-26.
13. Brunt EM, Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting, Mo Med, 2010,107(2):113-8.
14. Bugianesi E, Leone N, Vanni E, et al., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma, Gastroenterology, 2002,123(1):134-40.
15. Musso G, Gambino R, Cassader M, Pagano G, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 2011;43(8):6l7-49.
16. Bugianesi E, Bellentani S, Bedogni G, et al., clinical update on non-alcoholic fatty liver disease and steatohepatitis, Ann Hepatol, 2008;7(2):157-60.
17. Yki-järvinen H, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, 2014;pii;S2213-8587(14)70032-4.
18. Vanni E, Bugianesi E, Kotronen A, et al., From the metabolic syndrome to NAFLD or vice versa?, Dig Liver Dis, 2010;42(5):320-30.
19. Tilg H, Moschen AR, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology, 2010;52(5):1836-46.
20. Paradis V, Zallnski S, Chelbi E, et al., Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 2009;49(3):851-9.
21. Takuma Y, Nouso K, Nonalcoholic steatohepatitis-associated hepatocellular carcinoma Our case series and literature review, World J Gastroenterol, 2010;16(12):1436-41.
22. Targher G, Day CP, Bonora E, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease, N Engl J Med, 2010;363(14):1341-50.
23. Targher G, Bertolini L, Padovani R, et al., Associations between liver histology and carotid Intlma-media thickness in patients with nonalcoholic fatty liver disease, Arterioscler Thromb Vase Biol, 2005;25(12):2687-8.
24. Colak Y, Senates E, Yesil A, et al., Assessment of endothelial function in patients with nonalcoholic fatty liver disease, Endocrine, 2013;43(1):100-7.
25. Fracanzani AL, Burdick L, Raselli S, et al., Carotid artery intima-medla thickness in nonalcoholic fatty liver disease, Am J Med, 2008:121(1):72-8.
26. Villanova N, Moscatiello S, Ramilli s, et al., Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease, Hepatology, 2005:42(2):473-80.
27. Pacifico L, Anania C, Marlino F, et al., Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease, Hepatology, 2010,52(5):1643-51.
28. Brea A, Mosquera D, Martin E, et al., Nonalcoholic fatty liver disease is associated with carotid atherosclerosis, a case-control study, Arterioscler Thromb Vase Biol, 2005,25(5):1045-50.
29. Volzke H, Robinson DM, Kleine v, et al., Hepatic steatosis is associated with an increased risk of carotid atherosclerosis, World J Gastroenterol, 2005;11(12):1848-53.
30. Jung DH, Lee YJ, Ahn HY, et al., Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification, Clin Chem tab Med. 2010;48(12):1829-34.
31. Kim D, Choi SY, Park EH, et al., Nonalcoholic fatty liver disease is associated with coronary artery calcification, Hepatology, 2012;56(2):605-13.
32. Liu J, Musani SK, Bidulescu A, et al., Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study, Atherosclerosis, 2012;224(2):521-5.
33. Sookolan S, Pirola CJ, Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review, J Hepatol, 2008,49(4):600-7.
34. Yilmaz Y, Kurt R, Yonal O, et al., Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis, Atherosclerosis, 2010;211(1):182-6.
35. Lautamäki R, Borra R, Iozzo P, et al., Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes, Am l Physiol Endocrinol Metab, 2006;291(2):E282-90.
36. Nakamori S, Onishi K, Nakajima H, et al., Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging, Circ J, 2012;76(9):2234-40.
37. Açikel M, Sunay s, Koplay M, et al., Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity In patients undergoing coronary angiography, Anadolu Kardiyol Derg, 2009;9(4):273-9.
38. Wong VW, Wong GL, Yip GW, et al., Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease, Gut, 2011;60(12):1721-7.
39. Targher G, Pichiri I, Zopplni G, et al., Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease, J Endocrinol Invest, 2012;35(5):535-40.
40. Targher G, Bertolini L, Padovani R, et al., Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes, J Hepatol. 2010;53(4):713-8.
41. Treeprasertsuk S, Leverage S, Adams LA, et al., The Framingham risk score and heart disease in nonalcoholic fatty liver disease, Liver int, 2012;32(6):945-50.
42. Stepanova M, Younossi ZM, Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population, Clin Gastroenterol Hepatol. 2012;32(6):646-50.
43. Lazo M, Hernaez R, Bonekamp S, et al., Non-alcoholic fatty liver disease and mortality among US adults prospective cohort study, BMI, 2011;343:d6891.
44. Perseghin G. Lattuada G. De Cobelli F, et al., increased mediastinal fat and impaired left ventiicular energy metabolism in young men with newly found fatty liver, Hepatology, 2008;4701:51-8.
45. Bonapace S, Perseghin G, Molon G, et al., Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes, Diabetes Care, 2012;35(2):389-95.
46. Rijzewijk U, Tonker JT, van der Meer RW, et al., Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes, J Am Coll Cardiol, 2010;56(3):225-33.
47. Rijzewijk U, van der Meer RW, Smit JW, et al., Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus, J Am Coll Cardiol, 2008;52(22):1793-9.
48. Goland S, Shimoni S, Zornitzkl T, et al., Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment, I Clin Gastroenterol. 2006;40(10):949-55.
49. Mantovani A, Zoppini G, Targher G, et al., Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals,; Endocrinol Invest. 2012;35(2):215-8.
50. Hallsworth K, Hollingsworth KG, Thoma C, et al., Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease, J Hepatol, 2013:58(4):757-62.
51. Liu YC, Hung CS, Wu YW, et al., Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability, PLoS One, 2013;8(4):e61803.
52. Targher G, Mantovani A, Plchiri I, et al., Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes, Clin Sei Itond), 2013;125(6):301-9.
53. Sinner MF, Wang N, Fox CS, et al., Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation, Am J Cardiol, 2013;111(2):219-24.
54. Targher G, Valbusa F, Bonapace S, et al., Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes, Nutr Metab Cardiovasc Dis, 2014;24(6):663-9.
55. Wannamethee SG, Whincup PH, Shaper AG, et al., Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men, Arterioscler Thromb Vase Biol, 2012;32(3):830-5.
56. Markus MR, Baumeister SE, Stritzke J, et al., Hepatic steatosis is associated with aortic valve sclerosis in the general population: the study of Health in pomerania (SHIP), Arterioscler Thromb vase Biol, 2013;33(7):1690-5.
57. Bonapace S, Valbusa F, Bertolini L, et al., Nonalcoholic fatty liver disease is associated with aortic valve sclerosis In patients with type 2 diabetes mellitus, PLOS One, 2014;9(2):e88371.
58. Kim CH, Park JY, Lee KU, et al., Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults, Diabet Med, 2008,25(4):476-81.
59. Sung KC, Jeong WS, Wild SH, Byrne CD, Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes, Diabetes Care, 2012;35(4):717-22.
60. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G, Insulin resistance In nonalcoholic fatty liver disease, Curr Pharm Des, 2010;16(17):1941-51.
61. Toledo FG, Sniderman AD, Kelley DE, Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidomla in type 2 diabetes, Diabetes Care, 2006;29(8):1845-50.
62. Adiels M, Westerbacka J, Soro-Paavonen A, et al., Acute suppression of VLDLI secretion rate by insulin is associated with hepatic fat content and insulin resistance, Diabetologia, 2007;50(11):2356-65.
63. Adiels M, Taskinen MR, Packard C, et al., Overproduction of large VLDL particles is driven by increased liver fat content in man, Diabetologia, 2006;49(4):755-65.
64. Lerman A, Zeiher AM, Endothelial function: cardiac events, Circulation, 2005;111(3):363-8.
65. Schalkwijk CG, Stehouwer CD, Vascular complications In diabetes mellitus: the role of endothelial dysfunction, Clin Sci (Lond), 2005;109(2):143-59.
66. Pasarin M, Abraldes JG, Rodriguez-vilarrupla A, et al., Insulin resistance and liver microcirculation In a rat model of early NAFLD, J Hepatol, 2011;55(5):1095-102.
67. Pasarin M, La Mura V, Gracia-Sancho I, et al., Sinusoidal endothelial dysfuncrion precedes inflammation and fibrosis In a model of NAFLD, PloS One, 2012;7(4):e32785.
68. Francque S, Laieman W, Verbeke L, et al., Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture, Lab invest, 2012;92(10):1428-39.
69. Coulon S, Francque S, Colle I, et al., Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease, Cytohne, 2012;59(2):442-9.
70. Coulon S, Heindryckx F, Geerts A, et al, Angiogenesis in chronic liver disease and its complications, Liver Int, 2011:31(2):140-62.
71. Khurana R, Simons M, Martin JF, Zachary IC, Role of angiogenesis in cardiovascular disease: a critical appraisal, Circulation, 2005:112(12):1813-24.
72. Targher G, Chonchol M, Miele L, et al., Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome, Semin Thromb Hemost, 2009;35(3):277-87.
73. Van Gaal LF, Mertens IL, De Block CE, Mechanisms linking obesity with cardiovascular disease, Nature. 2006;444(7121):875-80.
74. Verrijken A, Francque S, Mertens I, et al., Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 2014;59(1):121-9.
75. Mertens I, van Gaal LF, Visceral fat as a determinant of fibrinolysis and hemostasis, Semin vase Med, 2005;5(1):48-55.
76. Ruige JB, Ballaux DP, Funahashi T, et al., Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders, Am I Clin Nutr. 2005;82(1):21-5.
77. Bruyndonckx L, Hoymans VY, Van Craenenbroeck AH, et al., Assessment of endothelial dysfunction in childhood obesity and clinical use, Oxid Med Cell Longev, 2013;2013:174782.
78. Bianchi G, Bugianesi E, Frystyk J, et al., Adiponectin isoforms, Insulin resistance and liver histology in nonalcoholic fatty liver disease, Dig Liver Dis, 2011;43(1):73-7.
79. Francque SM, Verrijken A, Mertens I, et al., Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients, Clin Gastroenterol Hepatol, 2012:10(10):1162-8.
80. Marra F, Bertolani C, Adipokines in liver diseases, Hepatology, 2009;50(3):957-69.
81. Ouedraogo R, Wu X, Xu SQ, et al., Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a CAMP signaling pathway, Diabetes, 2006;55(6):1840-6.
82. Adams V, Heiker JT, Höllriegel R, et al., Adiponectin promotes the migration of circulating angiogenic cells through p38-medlated induction of the CXCR4 receptor, Int 1 Cardiol 2013;167(5):2039-46.
83. Lima-Cabello E, Garcia-Mediavilla MV, Miquilena-Colina ME, et al., Enhanced expression of pro-inflammatory mediators and liver x-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C, Clin Sei (Lond), 2011;120(6):239-50.
84. Espinola-Kleln C, Gori T, Blankenberg S, Munzel T, Inflammatory markers and cardiovascular risk In the metabolic syndrome, From Biosci (Landmark Ed), 2011;16:1663-74.
85. Pihlajamäki J, Kuulasmaa T, Kaminska D, et al., Serum interleukin 1 receptor antagonist as an Independent marker of non-alcoholic steatohepatitis in humans, J Hepatol, 2012;56(3):663-70.
86. Mofrad P, Contos MJ, Haque M, et al., Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, 2003;37(6):1286-92.
87. Suzuki A, Lymp J, Sauver JS, et al., Values and limitations of setum aminotransferases in clinical trials of nonalcoholic steatohepatitis, Liver int. 2006;26(10):1209-16.
88. Bedogni G, Bellentani S, Mlglioli L, et al., The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol, 2006:6:33.
89. Angulo P, Hui JM, Marchesini G, et al., The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology. 2007,45(4):846-54.
90. Kotronen A, Peltonen M, Hakkarainen A, et al., Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors, Gastroenterology, 2009;137(3):865-72.
91. Younossi ZM, Jarrar M, Nugent C, et al., A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH), Obes Surg, 2008;18(11):1430-7.
92. Matteoni CA, Younossi ZM, Gramlich T, et al., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 1999;116(6):1413-9.
93. Dam-Larsen S, Franzmann M, Andersen IB, et al., Long term prognosis of fatty liver: risk of chronic liver disease and death, Gut, 2004:53(5):750-5.
94. Adams LA, Lymp JF, St Sauver J, et al., The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 2005,129(1):113-21.
95. Ekstedt M, Franzén LE, Mathiesen UL, et al., Long term follow-up of patients witn NAFLD and elevated liver enzymes, Hepatology, 2006;44(4):865-73.
96. Rafiq N, Bai C, Fang Y, et al., Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 2009;7(2):234-8.
97. Söderberg C, Stál P, Askling J, et al., Decreased survival of subjects with elevated liver function tests during a 28-year follow-up, Hepatology, 2010;51(2):595-602.
98. Musso G, Gambino R, Cassader M, Pagano G, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology. 2010;52(1):79-104.
99. Ratziu V, Pienar L, Pharmacological therapy for non alcoholic steatohepatitis: How efficient are thiazolidinediones?, Hepatol Res, 2011;41(7):687-95.
100. Ratziu V, Charlotte F, Bernhardt C, et al., Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology. 2010,51(2):445-53.
101. Sanyal AJ, Chalasani N, Kowdley KV, et al., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 2010;362(18):1675-85.
102. Mahady SE, Webster AC, Walker S, et al., The role of thiazolidinediones in non-alcoholic steatohepatitis-a systematic review and meta analysis, J Hepatol, 2011;55(6):1383-90.
103. Lassailly G, Caiazzo R, Pattou F, Mathurin P, Bariatuc surgery for curing NASH in the morbidly obese?, J Hepatol, 2013;58(6):1249-51.
104. Centis E, Marzocchi R, Suppini A, et al., The role ol lifestyle change In the prevention and treatment of NAFLD, Curr Pharm Des. 2013,19(29):5270-9.
105. Athyros VG, Tziomalos K, Gosslos TD, et al., Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis, Lancet, 2010;376(9756):1916-22.
106. Tikkanen MJ, Fayyad R, Faeigeman O, et al., Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels, Int J Cardiol. 2013,168(4):3846-52.
107. Genovese S, De Berardis G, Nicolticci A, et al., Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes, Adv Ther, 2013:30(2):190-202.
108. Zou C, Hu M, Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk, Vasc Health Risk Manag, 2013;9:429-33.
109. Vaccaro O, Masulli M, Bonora E, et al.; Addition of eithei pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial, Nutr Metab Cardiovasc Dis, 2012:22(11):997-1006.
110. Lexis CP, Wieringa WG, Hiemstra B, et al., Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction, Cardiovasc Drags Ther, 2014;28(2):163-71.
111. Lexis CP, van der Horst IC, Lipsic E, et al., Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial, JAMA, 2014;311(15):1526-35.
112. Preiss D, Lloyd SM, Ford I, et al., Metformin for non-diabetic patients with coronary heart disease (the CAMERA study):a randomised controlled trial, Lancet Diabetes Endocrinol, 2014;2(2):116-24.
113. Lexis CP, van der Horst IC, Metformin for cardiovascular disease: promise still unproven, Lancet Diabetes Endocrinol, 2014;2(2):94-5.